Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $59.02 down -7.42% from its previous closing price of $63.75. In other words, the price has decreased by -$7.42 from its previous closing price. On the day, 4.19 million shares were traded. CRSP stock price reached its highest trading level at $62.85 during the session, while it also had its lowest trading level at $58.68.
Ratios:
For a deeper understanding of CRISPR Therapeutics AG’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.64 and its Current Ratio is at 15.64. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on February 14, 2025, Upgraded its rating to Outperform and sets its target price to $99 from $60 previously.
On February 12, 2025, TD Cowen Upgraded its rating to Hold which previously was Sell but kept the price unchanged to $35.
On February 03, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $65.H.C. Wainwright initiated its Buy rating on February 03, 2025, with a $65 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 16 ’25 when George Simeon bought 989,812 shares for $52.03 per share. The transaction valued at 51,499,918 led to the insider holds 1,730,179 shares of the business.
Patel Naimish sold 3,932 shares of CRSP for $141,316 on May 29 ’25. The Chief Medical Officer now owns 6,068 shares after completing the transaction at $35.94 per share. On Mar 21 ’25, another insider, Kulkarni Samarth, who serves as the Chief Executive Officer of the company, sold 10,031 shares for $41.23 each. As a result, the insider received 413,578 and left with 195,085 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 5097185280 and an Enterprise Value of 3461257728. For the stock, the TTM Price-to-Sale (P/S) ratio is 135.31 while its Price-to-Book (P/B) ratio in mrq is 2.79. Its current Enterprise Value per Revenue stands at 91.871 whereas that against EBITDA is -7.603.
Stock Price History:
The Beta on a monthly basis for CRSP is 1.83, which has changed by 0.030197263 over the last 52 weeks, in comparison to a change of 0.15366066 over the same period for the S&P500. Over the past 52 weeks, CRSP has reached a high of $71.13, while it has fallen to a 52-week low of $30.04. The 50-Day Moving Average of the stock is 22.62%, while the 200-Day Moving Average is calculated to be 33.16%.
Shares Statistics:
For the past three months, CRSP has traded an average of 3.03M shares per day and 4253440 over the past ten days. A total of 86.36M shares are outstanding, with a floating share count of 81.79M. Insiders hold about 5.30% of the company’s shares, while institutions hold 68.88% stake in the company. Shares short for CRSP as of 1752537600 were 25295875 with a Short Ratio of 8.36, compared to 1749772800 on 21409921. Therefore, it implies a Short% of Shares Outstanding of 25295875 and a Short% of Float of 33.300000000000004.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
CRISPR Therapeutics AG (CRSP) is presently subject to a detailed evaluation by 19.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$1.31, with high estimates of -$0.83 and low estimates of -$1.68.
Analysts are recommending an EPS of between -$3.41 and -$6.71 for the fiscal current year, implying an average EPS of -$5.39. EPS for the following year is -$4.54, with 24.0 analysts recommending between $2.55 and -$6.82.
